Publications by authors named "C W Hudgens"
Article Synopsis
- Acral lentiginous melanoma (ALM) is a rare but aggressive form of skin cancer that mainly affects palms, soles, and nails, with higher occurrences in dark-skinned populations.
- A study assessed the expression of key proteins linked to tumor growth and treatment resistance (BCL2, MCL1, BIM, and BRAF V600E) in melanoma samples from White and Hispanic patients, noting no significant differences in protein expression between ALM and non-ALM tumors.
- The results suggest that since both ALM and non-ALM tumors frequently express these proteins, patients might benefit from new therapies aimed at inducing apoptosis (programmed cell death).
Article Synopsis
- Granulomatous Mycosis Fungoides (GMF) is a rare and severe type of mycosis fungoides that features a granulomatous infiltrate and generally has worse outcomes than typical mycosis fungoides.
- The study investigated immune responses in GMF and Mycosis Fungoides with Large Cell Transformation (MFLCT) by examining various markers in skin biopsies from 49 patients.
- Findings indicated that patients with GMF showed distinct immune profiles, including increased Tbet, RORγT, and PD-L1, while certain factors like low levels of RORγT and advanced disease stage correlated with poorer survival rates.
Article Synopsis
- Enfortumab vedotin (EV) is a targeted therapy for urothelial carcinoma, and this study evaluates its effectiveness for treating certain skin tumors by assessing Nectin-4 expression.
- Researchers analyzed various skin adnexal carcinomas and benign tumors through immunohistochemical staining, finding that malignant tumors had significantly higher Nectin-4 expression than benign ones.
- The study concludes that since many cutaneous adnexal carcinomas, particularly sebaceous carcinomas, exhibit high Nectin-4 levels, EV could be a viable treatment option for these cancers.
Deep penetrating nevi (DPN), particularly those showing combined features, or combined deep penetrating nevi (CDPN), may show histopathological resemblance to blue nevus (BN) and melanoma. Preferentially Expressed Antigen in MElanoma (PRAME) is a marker that helps distinguish melanoma from benign melanocytic lesions. Lymphoid enhancer-binding factor 1 (LEF1) has been proposed to be used in conjunction with β-catenin for diagnosis of DPN.
View Article and Find Full Text PDF